Showing results (1661-1670 of 6,770) with videos related to
Sort By:
Pageof 677
Clinical Therapeutics|May 22, 2012
Costs and clinical outcomes associated with use of ranolazine for treatment of anginaCharles E Phelps, Erin K Buysman, Gabriel Gomez ReyClinical Therapeutics|May 22, 2012
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in HungaryTibor Iványi, József Fövényi, Péter Faludi, et al.Clinical Therapeutics|July 30, 2013
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromesDanny Liew, Richard De Abreu Lourenço, Michael Adena, et al.Clinical Therapeutics|December 4, 2014
Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentaryVijayshree Yadav, Pushpa NarayanaswamiClinical Therapeutics|December 4, 2014
Role of clinical pharmacology in the development of antiplatelet drugsCarlo PatronoClinical Therapeutics|January 3, 2015
Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysisFeng Sun, Shanshan Wu, Jing Wang, et al.Clinical Therapeutics|December 3, 2014
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studiesAnn J Barbier, Martijn Hilhorst, André Van Vliet, et al.Clinical Therapeutics|August 25, 2014
Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countriesFrançois-Emery Cotté, Hicham Benhaddi, Isabelle Duprat-Lomon, et al.Clinical Therapeutics|March 26, 2013
Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United StatesJosh J Carlson, Ryan N Hansen, Roger R Dmochowski, et al.Clinical Therapeutics|March 26, 2013
Comparative-effectiveness research: does it matter?Joshua P CohenPageof 677